The objective of our analysis was to investigate the cost-effectiveness of atezolizumab versus chemotherapy as first-line therapy for EGFR and ALK wild-type metastatic NSCLC with different PD-L1 expression status from the Chinese health sector perspective. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.